当前位置: X-MOL 学术BMJ › 论文详情
Do PCSK9 inhibitors do anything more than reduce LDL cholesterol?
The BMJ ( IF 27.604 ) Pub Date : 2020-03-24 , DOI: 10.1136/bmj.m1159
Andrew N Bamji

Byrne and colleagues point out the lack of reliable evidence on cardiovascular risk with inclisiran, and the omens are not good.1 Inclisiran undoubtedly has a marked lowering effect on low density lipoprotein (LDL) cholesterol, which was first reported in 2017. But does a 30-50% reduction in LDL cholesterol translate to a 30-50% reduction in cardiovascular risk? Almost certainly not. The inclisiran results include an “exploratory cardiovascular endpoint” (a secondary …
更新日期:2020-03-26

 

全部期刊列表>>
全球疫情及响应:BMC Medicine专题征稿
欢迎探索2019年最具下载量的化学论文
新版X-MOL期刊搜索和高级搜索功能介绍
化学材料学全球高引用
ACS材料视界
南方科技大学
x-mol收录
南方科技大学
自然科研论文编辑服务
上海交通大学彭文杰
中国科学院长春应化所于聪-4-8
武汉工程大学
课题组网站
X-MOL
深圳大学二维材料实验室张晗
中山大学化学工程与技术学院
试剂库存
天合科研
down
wechat
bug